Esperion Therapeutics (ESPR) Inventory (2020 - 2026)

Esperion Therapeutics has reported Inventory for 7 years, with the latest figure at $104.2 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory rose 4.92% year-over-year to $104.2 million; the trailing twelve-month figure through Mar 2026 stood at $104.2 million (up 4.92% YoY), and the FY2025 full-year result was $105.1 million, up 11.25% from the prior year.
• Inventory for Q1 2026 stood at $104.2 million, down from $105.1 million in the prior quarter.
• The five-year high for Inventory was $114.5 million in Q2 2025, with the low at $29.2 million in Q2 2022.
• Historically, Inventory has averaged $70.3 million across 5 years, with a median of $73.1 million in 2024.
• Annual changes were most pronounced in 2022 — Inventory fell 13.03% — and 2023, when it surged 86.42%.
• Esperion Therapeutics' Inventory stood at $35.2 million in 2022, then surged by 86.42% to $65.6 million in 2023, then surged by 43.99% to $94.5 million in 2024, then increased by 11.25% to $105.1 million in 2025, then dropped by 0.87% to $104.2 million in 2026.
• The last three Inventory figures came in at $104.2 million (Q1 2026), $105.1 million (Q4 2025), and $108.5 million (Q3 2025), per Business Quant data.